Multiple Adverse Reactions Associated With the Use of Second-Generation Antipsychotics in People With Alzheimer’s Disease: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System

Alzheimer's disease (AD) is a neurodegenerative condition leading to memory loss, cognitive impairment, and neuropsychiatric symptoms. Second-generation antipsychotics (SGAs) are commonly used to manage these neuropsychiatric symptoms, but their safety profile in patients with AD requires further investigation.